Critical Survey: Ascentage Pharma Group International (NASDAQ:AAPG) & X4 Pharmaceuticals (NASDAQ:XFOR)

Ascentage Pharma Group International (NASDAQ:AAPG) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Ascentage Pharma Group International and X4 Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0	0	8	2	3.20
X4 Pharmaceuticals	1	1	4	0	2.50

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 176.85%. X4 Pharmaceuticals has a consensus price target of $9.38, indicating a potential upside of 133.21%. Given Ascentage Pharma Group International’s stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than X4 Pharmaceuticals.

Insider and Institutional Ownership

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Ascentage Pharma Group International has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ascentage Pharma Group International and X4 Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$574.12 million	2.73	-$177.71 million	N/A	N/A
X4 Pharmaceuticals	$35.11 million	10.80	-$79.20 million	($4.54)	-0.89

X4 Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International.

Profitability

This table compares Ascentage Pharma Group International and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

Summary

Ascentage Pharma Group International beats X4 Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.